Get started

Financials · CCEL

Cryo-Cell International Inc. (CCEL) financials

For the twelve months ended Aug 31, 2026, Cryo-Cell International Inc. reported $31.13M of revenue and -$1.95M of net income.

Revenue, TTM
$31.13M
Revenue growth, YoY
-2.0%
Net income, TTM
-$1.95M
Net margin
-6.2%
Free cash flow, TTM
$4.65M
EPS, diluted, TTM
-$0.22
Cash
$1.43M
Total debt
$8.24M
P/S
1.27
Market cap
$39.4M
Annual revenue$31.57M
FY2016FY2025
Annual net income-$2.43M
FY2016FY2025
Annual free cash flow$5.25M
FY2016FY2025

CCEL revenue and earnings growth

CCEL revenueQ3 2026$7.82M

Quarter YoY
-0.0%
QoQ
+0.6%
FY YoY
-1.3%
5Y CAGR
+0.3%
10Y CAGR
+4.1%

CCEL revenue was $7.82M in fiscal Q3 2026 (ended Aug 31, 2026), down 0.0% from a year earlier and up 0.6% from the prior quarter. For the full fiscal 2025 it was $31.57M, down 1.3% from fiscal 2024. Compound annual growth was +0.3% over 5 years and +4.1% over 10 years. It rose in 7 of the last 10 fiscal years.

CCEL net incomeQ3 2026$1.27M

Quarter YoY
+69.5%
QoQ
+129.1%

CCEL net income was $1.27M in fiscal Q3 2026 (ended Aug 31, 2026), up 69.5% from a year earlier and up 129.1% from the prior quarter. For the full fiscal 2025 it was -$2.43M, compared with $402.1K in fiscal 2024.

CCEL EPSQ3 2026$0.16

Quarter YoY
+77.8%
QoQ
+128.6%

CCEL diluted EPS was $0.16 in fiscal Q3 2026 (ended Aug 31, 2026), up 77.8% from a year earlier and up 128.6% from the prior quarter. For the full fiscal 2025 it was -$0.30, compared with $0.05 in fiscal 2024.

CCEL free cash flowQ3 2026$1.04M

Quarter YoY
-58.4%
QoQ
-42.6%
FY YoY
+45.5%
5Y CAGR
-8.9%
10Y CAGR
+1.0%

CCEL free cash flow was $1.04M in fiscal Q3 2026 (ended Aug 31, 2026), down 58.4% from a year earlier and down 42.6% from the prior quarter. For the full fiscal 2025 it was $5.25M, up 45.5% from fiscal 2024. Compound annual growth was -8.9% over 5 years and +1.0% over 10 years.

Export CSV

Income statement

Income statement
Line item
FY2025
Nov 30, 2025
FY2024
Nov 30, 2024
FY2023
Nov 30, 2023
FY2022
Nov 30, 2022
FY2021
Nov 30, 2021
FY2020
Nov 30, 2020
FY2019
Nov 30, 2019
FY2018
Nov 30, 2018
FY2017
Nov 30, 2017
FY2016
Nov 30, 2016
Revenue$31.57M$31.99M$31.34M$30.34M$28.88M$31.15M$31.82M$29.22M$25.38M$23.13M
Cost of revenue$7.38M$7.95M$8.39M$8.79M$8.99M$9.66M$10.04M$8.54M$6.72M$5.77M
Gross profit$24.19M$24.04M$22.95M$21.54M$19.90M$21.49M$21.78M$20.68M$18.66M$17.35M
Research and development$376.3K$1.24M$1.17M$384.8K$49.9K$23.9K$30.1K$91.8K$41.2K$53.1K
Selling, general and admin$18.22M$18.52M$17.17M$15.58M$14.61M$14.29M$14.89M$15.63M$13.48M$14.72M
Operating income$482.4K$3.48M-$12.30M$4.02M$4.02M$7.66M$5.06M$5.19M$5.01M$433.6K
Interest expense$2.07M$1.86M$1.24M$1.52M$1.38M$1.54M$1.70M$1.55M$1.30M$947.3K
Pre-tax income-$2.34M$2.80M-$13.36M$3.32M$2.61M$5.04M$3.39M$3.62M$3.62M-$2.48M
Income tax$92.2K$2.40M-$3.84M$547.5K$527.7K$1.41M$1.10M$4.47M$1.31M-$1.16M
Net income-$2.43M$402.1K-$9.52M$2.77M$2.08M$3.62M$2.29M-$854.8K$2.32M-$1.32M
EPS, basic-$0.30$0.05-$1.14$0.33$0.26$0.48$0.29-$0.11$0.33-$0.16
EPS, diluted-$0.30$0.05-$1.14$0.33$0.25$0.45$0.27-$0.11$0.30-$0.16
Diluted shares8.1M8.2M8.3M8.5M8.4M8.1M8.4M7.5M7.7M8.1M

Balance sheet

Balance sheet
Line item
FY2025
Nov 30, 2025
FY2024
Nov 30, 2024
FY2023
Nov 30, 2023
FY2022
Nov 30, 2022
FY2021
Nov 30, 2021
FY2020
Nov 30, 2020
FY2019
Nov 30, 2019
FY2018
Nov 30, 2018
FY2017
Nov 30, 2017
FY2016
Nov 30, 2016
Cash and equivalents$319.0K$561.0K$406.1K$1.70M$8.26M$10.36M$6.54M$6.04M$6.28M$3.50M
Short-term investments$2.98M$2.94M$574.2K$17.6K$75.4K$88.5K$904.1K$875.7K$439.3K$624.2K
Receivables$6.85M$7.31M$6.58M$6.04M$5.25M$6.32M$6.10M$5.87M$5.13M$4.05M
Inventory$408.8K$657.7K$768.9K$851.2K$921.2K$927.3K$1.08M$1.26M$314.6K$361.1K
Current assets$11.76M$12.55M$9.45M$9.61M$15.78M$18.56M$15.39M$14.76M$12.74M$9.01M
Goodwill$1.94M$1.94M$1.94M$1.94M$1.94M$1.94M$1.94M$1.94M$0$0
Total assets$61.73M$64.68M$64.68M$64.89M$60.66M$46.20M$42.89M$42.89M$23.91M$19.54M
Current liabilities$19.79M$21.60M$20.86M$19.48M$21.07M$16.41M$15.43M$15.43M$13.94M$13.11M
Long-term debt-------$1.43M$1.43M$1.43M
Total debt$8.35M$8.48M$8.60M$8.73M$1.90M$5.94M$8.96M$1.43M$1.43M$1.43M
Total liabilities$80.33M$77.89M$72.25M$66.41M$56.48M$48.87M$49.84M$51.30M$36.41M$34.95M
Shareholders' equity-$18.61M-$13.22M-$11.03M-$1.52M$4.18M-$2.67M-$6.95M-$8.91M-$12.50M-$15.41M

Cash flow

Cash flow
Line item
FY2025
Nov 30, 2025
FY2024
Nov 30, 2024
FY2023
Nov 30, 2023
FY2022
Nov 30, 2022
FY2021
Nov 30, 2021
FY2020
Nov 30, 2020
FY2019
Nov 30, 2019
FY2018
Nov 30, 2018
FY2017
Nov 30, 2017
FY2016
Nov 30, 2016
Operating cash flow$5.48M$6.01M$8.92M$8.57M$7.93M$8.47M$6.29M$5.33M$5.72M$4.99M
Capital expenditures$230.5K$2.40M$6.84M$12.17M$1.83M$100.0K$662.3K$446.2K$98.3K$343.0K
Free cash flow$5.25M$3.61M$2.08M-$3.60M$6.09M$8.37M$5.63M$4.89M$5.62M$4.64M
Investing cash flow-$975.3K-$4.88M-$8.14M-$15.28M-$6.95M$357.5K-$662.3K-$11.28M$93.0K-$369.7K
Financing cash flow-$4.75M-$979.1K-$2.07M$147.9K-$3.07M-$5.00M-$5.13M$5.71M-$3.03M-$5.27M
Dividends paid$3.23M$2.02M$0$7.67M$0-----
Share repurchases$169.5K$1.42M$799.0K$1.82M$249.4K-$992.2K-$446.6K$10.81M
Stock-based compensation$417.1K$781.1K$816.6K$461.3K$301.6K$622.1K$397.8K$478.4K$971.7K$1.77M
Depreciation and amortization$985.2K$693.8K$1.40M$1.50M$1.04M$372.3K$401.3K$317.3K$131.6K$154.7K

Key ratios

Key ratios
Line item
FY2025
Nov 30, 2025
FY2024
Nov 30, 2024
FY2023
Nov 30, 2023
FY2022
Nov 30, 2022
FY2021
Nov 30, 2021
FY2020
Nov 30, 2020
FY2019
Nov 30, 2019
FY2018
Nov 30, 2018
FY2017
Nov 30, 2017
FY2016
Nov 30, 2016
Revenue growth, YoY-1.3%2.0%3.3%5.0%-7.3%-2.1%8.9%15.1%9.8%9.7%
Net income growth, YoY---33.0%-42.5%58.2%----
EPS growth, YoY---32.0%-44.4%66.7%----
Gross margin76.6%75.2%73.2%71.0%68.9%69.0%68.5%70.8%73.5%75.0%
Operating margin1.5%10.9%-39.3%13.3%13.9%24.6%15.9%17.8%19.7%1.9%
Net margin-7.7%1.3%-30.4%9.1%7.2%11.6%7.2%-2.9%9.1%-5.7%
Free cash flow margin16.6%11.3%6.6%-11.9%21.1%26.9%17.7%16.7%22.1%20.1%
Return on equity----49.8%-----
Return on assets-3.9%0.6%-14.7%4.3%3.4%7.8%5.3%-2.0%9.7%-6.8%
Current ratio0.590.580.450.490.751.131.000.960.910.69
Debt to equity----0.45-----

Source: XBRL data Cryo-Cell International Inc. files with the SEC, latest filing dated Oct 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CCEL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CCEL$31.13M-2.0%-$1.95M-6.2%$39.4M
FMS€19.63B+1.5%€978.37M5.0%$13.07B
DVA$14.17B+6.4%$920.08M6.5%$12.04B
SHC$1.23B+6.9%$173.47M14.1%$4.57B
PGNY$1.34B+5.5%$91.02M6.8%$2.67B
AGL$6.00B+2.0%-$87.10M-1.5%$1.90B
VMD$310.37M+21.8%$15.89M5.1%$346.0M
NIVF$23.71M+336.3%$9.88M41.7%$4.5M

CCEL FAQ

9 questions
  • What is CCEL revenue?
    Cryo-Cell International Inc. (CCEL) reported $31.13M of revenue for the twelve months ended Aug 31, 2026. That is down 2.0% from the year before. Revenue for fiscal 2025 was $31.57M.
  • Is CCEL profitable?
    No. Cryo-Cell International Inc. reported a net loss of $1.95M for the twelve months ended Aug 31, 2026.
  • How much cash and debt does CCEL have?
    Cryo-Cell International Inc. reported $1.43M in cash and cash equivalents and $8.24M of debt on its most recent balance sheet in SEC filings.
  • How fast is CCEL revenue growing?
    Cryo-Cell International Inc.'s revenue changed -1.3% in fiscal 2025, to $31.57M. Its compound annual growth rate was +0.3% over 5 years and +4.1% over 10 years.
  • What is CCEL gross margin?
    Cryo-Cell International Inc.'s gross profit was $24.45M on $31.13M of revenue for the twelve months ended Aug 31, 2026, a gross margin of 78.5%.
  • What is CCEL free cash flow?
    Cryo-Cell International Inc. generated $4.65M of free cash flow for the twelve months ended Aug 31, 2026, which is operating cash flow of $4.92M less capital expenditures.
  • What is CCEL earnings per share?
    Diluted earnings per share were -$0.22 for the twelve months ended Aug 31, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CCEL last report financial results?
    The latest statements here come from Cryo-Cell International Inc.'s 10-Q filed on Oct 9, 2026, covering the period ended Aug 31, 2026.
  • Where does this CCEL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cryo-Cell International Inc. files with the SEC. It is provided for information only and is not investment advice.